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Infantile haemangioma (IH), considered a primary tumour of the 
microvasculature, is the most common tumour of infancy affecting about 10% of 
Caucasian infants. IH predominantly affects white, female and premature infants. IH 
typically undergoes an initial rapid proliferation during infancy (proliferative phase) 
characterised by aggressive angiogenesis, followed by spontaneous involution over 
the next 1-5 years (involuting phase) and continued improvement up to 10 years 
(involuted phase), often with a fibro-fatty residuum. IH consists of cells of various 
lineages, with the presence of mesenchymal stem cells, endothelial progenitor cells, 
endothelial cells, myeloid haematopoietic cells, and pericytes. This thesis 
demonstrates the expression of primitive (stem/progenitor cell) markers on the 
endothelium of IH. The expression of the transcription factors brachyury, Tal-1 and 
GATA-2, along with the demonstration of erythropoiesis in IH explants in vitro 
supports the hypothesis that IH consists of a primitive endothelium similar to an 
embryonic haemogenic endothelium. The expression of the erythropoietin receptor 
and haemoglobin zeta chain by the endothelium of IH further strengthens the notion 
that IH is a haemogenic endothelium. Consistent with the primitive embryonic origin, 
the expression of the placental markers human chorionic gonadotrophin (hCG) and 
human placenta lactogen (hPL), but not cytokeratin 7 (CK7) or human leucocyte 
antigen- G (HLA-G) by the endothelium in IH, supports a placental chorionic villous 
mesenchymal core cell, and not a trophoblast, origin for IH. IH thus has an extra-
embryonically derived primitive mesodermal origin. This primitive mesoderm is able 
to account for the haemogenic endothelium phenotype of the endothelium of 
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proliferating IH microvessels with its capacity for both erythropoietic and 
mesenchymal differentiation.  
Additionally, data are presented to show that IH expresses key components 
of the renin-angiotensin system (RAS), angiotensin converting enzyme (ACE), 
angiotensin II (ATII), angiotensin receptor 2 (ATR2). Cultured IH-derived stem cells 
can be induced to proliferate and form blast colonies in response to ATII treatment. 
The crucial regulatory role of RAS in the proliferation and differentiation of the 
stem/progenitor cell population within IH accounts for the natural progression of IH. A 
model is proposed to provide a rational explanation for the serendipiditous discovery 
of the dramatic effect that the β-blocker, Propranolol has in accelerating involution of 
IH.  The hypothesis that Propranolol exerts its action on IH through modulation of the 
RAS by blocking renin activity and preventing the conversion of angiotensinogen to 
angiotensin I, thereby reducing ATII levels, has led to a clinical trial using Captopril, 
an ACE inhibitor in the treatment of problematic proliferating IH.  The observed 
accelerated involution of IH by Captopril which blocks the conversion of angiotensin I 
to ATII confirms a key regulatory role for RAS in the biology of IH  This discovery 
underpins the development of potentially safer and novel treatment modalities for this 
enigmatic condition. 
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Vascular anomalies (VA) are localised defects in the structure of the 
vasculature. There has been considerable confusion in the terminology in the 
literature leading  to inappropriate treatment and misdirected research efforts. 
The term haemangioma has been used to describe all the forms of vascular 
anomalies. In 1982 Mulliken and Glowacki1 proposed a classification of 
vascular anomalies, based on biology, into haemangioma and vascular 
malformations. This classification was adapted by the International Society for 
the Study of Vascular Anomalies (ISSVA) in 1996. 
Haemangioma, is the most common tumour of infancy (Figure 1.1), 
commonly referred to as infantile haemangioma (IH) or colloquially, 




IH affects approximately 10% of Caucasian infants 2,3 with a lower incidence 
in dark skin races. It is more common in Caucasian, female, and in premature 







Most IHs are not present at birth with 40% evident in the first two weeks of life. 
IH typically presents as a small red mark or an area of telangiectasia with a 
surrounding pale halo and undergoes rapid proliferating within the first year of 
life (proliferative phase)1. This is followed by a spontaneous involution over 
the next five years (involuting phase), with on-going improvement up to 10 
years (involuted phase) usually leaving a fibrofatty residuum (Figure 1.2)2,5,6 
(Figure 1 A-D). The endothelium of IH expresses the immunohistochemical 
marker glucose transporter-1 (GLUT-1) that distinguishes IH from other forms 
of vascular anomalies6. Sixty percent of IH occur in the head and neck region, 
with lesions in the trunk and extremities making up for 25 and 15 percent 
respectively. 
            
Figure 1.1. Serial images of a child with a large facial IH at 2 weeks (A), 1 










Figure 1.2. Haematoxylin and eosin staining of representative IH sections taken 
during proliferation (A), involuting (B) and involuted (C) phases demonstrating the 




IH commonly presents as discrete localised lesions mostly affecting the skin 
and/or subcutaneous tissues7. It may involve any other tissues or organs such 
as liver, spleen, gut, lung, bladder and adrenal glands8. Multiple cutaneous 
lesions are not uncommon9, with an increased risk of hepatic involvement with 
increasing number of cutaneous lesions9,10.  
Focal lesions present as localised lesions mostly affecting the face7 
(Figure 1.3). Segmental lesions are generally more extensive and plaque-like. 
The segmental distribution of these IHs corresponds to the embryological 
mesenchymal prominences of the head and neck development, i.e., 
frontonasal, maxillary or mandibular11 (Figure 1.4). 






Figure 1.3. Localised focal IH lesions on the forehead (A), left cheek (B) and left 
upper lip (Courtesy of Professor Swee T. Tan).    
 
       
Figure 1.4. Segmental IHs in the left frontal (A), right maxillary (B), and mandibular 




PHACES syndrome is a neurocutaneous syndrome affecting a sub-group of 
patients with segmental IHs, in which the segmental IH is associated with one 
or more of the following features: Posterior fossa malformations of the brain, 
arterial anomalies, cardiac anomalies, aortic coarctation, eye abnormalities, 
sterna cleft and/or supraumbilical raphe (Figure 1.5)12,13. The observed 
subtype of IH and in particular, the association with midline structural 
anomalies are unexplained. 






Figure 1.5. A child with PHACES syndrome demonstrating segmental facial IH with 




There is a small subgroup of IHs that are fully grown at birth and they have 
been called congenital haemangiomas 14,15. Congenital haemangiomas  are 
further sub-categorised into (1) Rapidly involuting  congenital haemangioma 
(RICH)15, which regresses completely by 10-14 months of age, and (2) Non-
involuting congenital haemangioma (NICH)14, which never regresses and 
grows proportionally with the child. RICH and NICH share similar histological 
features with the common IH.  However, unlike IH they do not express GLUT-







Approximately 50% of IH will regress by age five and all be age 1016 with 
approximately 25% requiring surgery and or laser therapy during the 
involuting and involuted phases17. The self limiting and benign progression of 
the majority of IH renders an expectant management approach being adopted. 
However, 10-14% of IH require active intervention during the proliferative 
phase because of its threat to life or function or tissue distortion or 
destruction18,19 as the result of the involvement of critical organs, such as the 
airways, eyes, liver, and ulceration. 
The heterogeneity and innate tendency for IH to involute provides an 
exciting and equally challenging dilemma for the physician caring for infants 
with IH. It is the ability to predict those patients in need of treatment or with 
the highest risk of a complication that provides the greatest challenge for 
physicians. A study in 2006 of over one thousand patients with IH revealed 
that morphological subtype and anatomical location were by far the greatest 
predictors of complication and the requirement for treatment20. Of the 
morphologic subtypes, segmental IHs were by far more likely to require 
treatment compared to localised lesions, by a factor of greater than 10. When 
accounting for anatomical location, perineal IHs were noted to have the 
highest rate of ulceration, although fortunately this location is relatively 
uncommon. Facial IH on the other hand represents the most common location 
for IH, accounting for a proportionately higher rate of the need for active 
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Table 1.1. Features of IH with the highest risk of morbidity according to anatomic 




It is noteworthy that the identification of chemotherapeutic agents suitable for 
the treatment of problematic IH has predominantly been serendipitously 
discovered. 
The mainstay treatment for problematic IH is pharmacological with high 
dose corticosteroids being first line agents21. More recently vincristine22 has 
replaced interferon23 as second line treatment in cases that failed 
corticosteroid therapy. However, since their serendipitous discovery, β-
blockers24,25 have now surpassed corticosteroids as the first choice of treating 
problematic IH in many centres26,27. Recent use of propranolol and a review 
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on the treatment and future possible therapies for IH is discussed in depth in 






IH has traditionally been regarded as a benign tumour of the microvasculature 
with proliferating lesions composed of immature microvessels, that are lined 
by plump, mitotically active endothelial cells, characterised by the expression 
of endothelial markers (CD31, vWF, Ulex europaes, and CD34)2,28.  
Cells that are phenotypically similar to endothelial cells have been 
isolated from proliferating IHs and characterised and their similarities to 
endothelial cells isolated from second trimester fetal tissues have been 
observed29. Other studies have suggested a clonal origin for the endothelial 




Post-natally, all haematopoietic cells are generated in the bone marrow from 
pluripotent haematopoietic stem cells, where the lymphoid and myeloid 
lineages diverge. Myeloid progenitors generate granulocyte/macrophage 
progenitors in the marrow and upon entering the circulation, forms 
downstream myeloid lineages known as the polymorphonuclear leucocytes, 
monocytes and mast cells31. 
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The abundance of mast cells within IH has been noted to be 
predominantly localised to the interstitium, and the numbers tended to 
increase as the tumour involuted4. The role of mast cells in the involution of IH 
has been attributed to their production of pro-apoptotic proteins during 
involution4. Fig. 1.6 shows mast cells located within the interstitium of a 
proliferating IH.  
It is interesting that another study identifying haematopoietic leucocytes 
also noted interstitial localisation of this population within IH with a 
proportional decrease during involution, suggesting a role for secretion of 
cytokines32 from these myeloid cells during IH progression. 
The source of these myeloid cells seen in abundance within IH is 




Figure 1.6. Mast cells in proliferating IH. Mast cells were identified in IH by counter-
staining for chymase (brown DAB staining). The brown cells (arrows) are located in 






Pericytes are mural cells proposed to originate post-natally in the bone 
marrow/stroma which are recruited into areas of angiogenesis to form the 
pericytes, to provide support for the endothelial cells.  
Pericytes have been characterised by their expression of smooth 
muscle actin (SMA)34. Immunohistochemical (IHC) studies of IH have 
revealed an inner cell layer characterised by the expression of endothelial 





Adipocytes form the predominant cell type within the fibrofatty residuum in 







Endothelial progenitor cells (EPCs) have been deemed haematopoietic 
progenitor cells, generated in the bone marrow and possessing the innate 
ability to differentiate into cells of the endothelial lineage35. EPCs have been 
characterised by the expression of CD133, CD34 and VEGFR-235. Whether 
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these EPCs exist as a distinct entity within the spectrum of haematopoietic-
endothelial differentiation, or whether they simply reflect a transitional state 
remains unresolved.  
EPCs have been identified within proliferating IH36, and there is an 
increased level of these cells in the circulation of affected patients37. These 
EPCs have been proposed to be the precursors to the endothelial cells that 
predominate in proliferating lesions. These EPCs have been proposed to 
originate from the bone marrow and recruited into IH. However, the chemical 




Mesenchymal stem cells (MSCs), more appropriately called mesenchymal 
progenitor cells (MPCs), have been characterised by three main properties 
including: (i) the expression of mesenchymal associated proteins such as 
CD29, CD44, CD90, and vimentin, (ii) the adherence to plastic in culture, and 
(iii) the ability to differentiate and form terminal mesenchymal derived cells 
such as adipocytes, osteoblasts and chrondrocytes33. True MPCs do not 
express endothelial or haematopoietic associated markers33,38. 
The presence of a mesenchymal progenitor population within 
proliferating IH was demonstrated by Yu et al39. They based the isolation of 
these cells predominantly on their adherence to plastic. Yu’s report also 
highlighted the characterisation of these MPCs following at least ten passages 
in culture, and revealed the expression of mesenchymal-only associated 
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proteins, with the exclusion of haemato/endothelial markers. They were also 
able to demonstrate adipocyte and osteoblast differentiation capacity in this 
cell population. It has been suggested that these mesenchymal progenitors 
which give rise to the fatty tissue seen during involution,  have been recruited 




Neural crest cells are bilaterally paired epithelial cells arising from the 
ectoderm at the margins of the neural tube. These cells undergo an epithelial-
mesenchymal transition (EMT), such that they undergo a change in 
phenotype and transform into migratory mesenchymal cells, which migrate to 




There are two distinct patterns of neural crest cell migration relating to 
anatomical location. In the cephalic region, neural crest cells migrate into the 
pharyngeal arches forming tissues of ectomesenchymal origin, and contribute 
to the formation of the facial skeleton, fat, connective tissue, teeth, 
melanocytes and peripheral neurons41,42. 
In contrast, in the trunk region, neural crest cells contribute to the 






Figure 1.7. Illustration of the lineage differentiation capacity of neural crest cells 




Neural crest cells are characterised by the expression of various cell surface 
and cytosolic proteins. Three such neural crest associated proteins namely 
p75, Sox 9 and Sox 10 are discussed in this thesis. Low-affinity nerve growth 
factor receptor (LNGFR), also known as neurotropin/p75, is a cell surface 
marker typically identifying neural crest cells. Sox 9 and Sox 10, are members 
of the group E Sox genes, which play an important role in the development of 
neural crest cells both at the induction of neural crest cell stage and at the 
migratory stage43. It is relevant that Sox 9 is also expressed in many other cell 






Human embryonic stem cells (hESCs) have provided an invaluable in vitro 
model for studying human development including the induction and 
differentiation of the nervous system. 
A recent report by Lee et al45, shows that the differentiation and 
isolation of human neural crest stem cells from a hESC line involved the 
addition of fibroblast growth factor 2 or bone morphogenic protein 245. It is 
exciting that the authors note the neuronal differentiation capacity of these 
ESC-derived neural crest cells, which can further differentiate into 
downstream neurons through the addition of cytokines of which nerve growth 
factor (NGF) and the second messenger cyclic AMP play a critical role. It is 
interesting  that the addition of serum to the culture medium of these neural 
crest stem cells induces their differentiation into mesenchymal cells. Figure 
1.8, summarises the findings of the bi-potent nature of these ESC-derived 
neural crest cells. This dual potential of ESC-derived neural crest cells strikes 
parallels with neural crest cells derived from IH tissues, and highlights the 
similarities between these populations, which will be the topic of investigation 
in this thesis. The differentiation capacity of mesenchymal cells to form 
terminal mesenchymal tissues such as adipocytes, and osteoblasts has been 





Figure 1.8. Shows lineage characterisation and differentiation of ESC-derived neural 
crest stem cells with the ability to form downstream neuronal and mesenchymal 






Osteoprotegerin (OPG) is a secreted glycoprotein belonging to the tumour 
necrosis factor (TNF) receptor family, and has been identified in both the   
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and 
(receptor for nuclear factor κB ligand (RANKL) pathways46. TRAIL, also 
known as Apo2L, and its soluble decoy receptor, OPG, have been implicated 
in the pathogenesis of IH11. TRAIL, acting via receptors, namely death 
receptors 4 and 5 (DR4 and DR5) induce cells to undergo apoptosis. 
However, binding of TRAIL to its decoy receptors, DcR1 and DcR2, prevents 
apoptosis. We have previously demonstrated the presence of OPG on the 
immature capillaries of proliferating IH, which is lost as the microvessels 
mature. We postulate that OPG acting through the TRAIL pathway prevents 




OPG has been shown to be a soluble decoy receptor for TRAIL, as well as a 
regulator of bone remodelling through its action on the receptor for RANKL. 
RANKL is also a member of the TNF superfamily and is expressed in the 
bone marrow environment47. RANKL is the ligand for its receptor RANK, 
which is primarily expressed on osteoclast precursors. The binding of RANKL 
to RANK receptors triggers osteoclast recruitment and differentiation. OPG on 
the other hand has been demonstrated to bind to RANKL and inhibits the 
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The haematopoietic system in humans is one of the first major organs to form, 
because of its crucial role in supplying oxygen to the growing foetus48. The 
haematopoietic system consists of a series of hierachical regulation of 
pluripotent haematopoietic stem cells down to functionally terminally 
differentiated and distinct blood cells49. It is this regulation of differentiation 
and proliferation of haematopoietic stem cells to eventual downstream 





In humans the haematopoietic stem cell pool is already formed during 
embryogenesis. There are two waves of embryonic haematopoiesis namely 





Primitive, or ventral, haematopoiesis occurs outside the embryo, i.e., extra-
embryonic, in the yolk sac from around day 17 to around day 40 of gestation 
(Figure 1.9)50,51. This extra-embryonic haematopoietic process  involves the 
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initial aggregation of primitive mesoderm cell aggregates, the internal cells 
simultaneously disappearing to form the first open vessel lumen with a few 
primitive mesodermal cells adhering to the de-novo endothelium to form 
structures known as blood islands50. During this early stage of 
haematopoiesis erythoid cells predominant, with reports of megakaryocytes 
and macrophages also being present. 
 
Figure 1.9. The chronological appearance of haematopoietic sites in the human 




The onset of definitive haematopoiesis coincides with the onset of the cardiac 
rhythm and hence the onset of the circulation51. The onset of the circulation 
allows the primitive yolk-sac derived blood cells to enter the embryonic tissues 
and therefore colonise the embryonic sites of haematopoiesis.  It is at about 
the day 23 stage that the liver is initially colonised and forms the first major 
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organ for definitive haematopoiesis, and the first major haematopoietic organ 
in the foetus, but the role for the embryonic liver to function as a 
haematopoietic organ has been attributed to a second wave of colonisation 
that takes place at the day 30 stage50. 
It is interesting to note that from day 27 a transient site of intra-
embryonic haematopoiesis has also been demonstrated in the umbilical 
region of the aorta and the vitelline artery . This site of haematopoiesis 
becomes prominent at day 35, with clusters of thousands of cells clearly 
visible, which then disappear after day 40 gestation50.  
Bone marrow haematopoiesis is the main adult haematopoietic forming 
tissue, which starts during the 11th week of gestation. Haematopoiesis in the 
bone marrow develops within mesodermal structures, known as logettes. 
These logettes are composed of a network of mesenchymal cells supported 
by dense fibrillar material surrounding a central artery (Figure 1.10)52. The 
earliest progeny that differentiate from the bone marrow are CD15+ myeloid 




Figure 1.10. IHC slide showing staining of a logette for CD34+ endothelial cells which 
are surrounded by CD34-/SMA+, and a surrounding sinus (S) lined by CD34+ 




The first site of mammalian intra-embryonic haematopoiesis is in the region of 
the dorsal aorta. As stated earlier, the lack of an in vivo human model means 
that most of these studies have been performed on murine models of 
development50.  This period of development in the mouse embryo at E10.5 - 
11.5 is characterised by the developing aorta becoming flanked by the 
gonado-mesonephric columns, and hence the region has been appropriately 
referred to as the Aorto-Gonado-Mesonephros (AGM). It is during this period 
of gestation that haematopoietic cells can be seen budding off from the aorta, 
and it is this concept of haematopoietic cells generated from an endothelial 
phenotype that forms the basis of the concept of the haemogenic 
endothelium53. Although there is some debate as to whether these 
haematopoietic cells are indeed derived from the endothelium or from its 
underlying mesenchyme54,a report by Zovein et al55 confirms, through lineage 




The notion of a common precursor to both cells of the endothelial and 
haematopoietic lineages, has formed the basis for the hypothesis of a 
common precursor, the so called haemangioblast56. However, the direct in 
vitro demonstration of the haemangioblast was not achieved until 199857,58. 
34 
 
Subsequent studies have demonstrated the derivation of haemangioblasts 
from ESCs via a primitive mesoderm intermediate, with the ability to form dual 
lineages (Figure 1.11)59,60.  
 
Figure 1.11. The ESC origin of the haemangioblast. Haemangioblast has the ability 
to differentiate and form downstream endothelial and haematopoietic lineages 










The ontogeny of the development of haemoglobin in humans mirrors the 
changes in the sites of erythropoiesis during human development. Mirroring 
these switches are the changes in the globin gene expression, from 
embryonic (ζ2ε2) to foetal haemoglobin (α2γ2) at around seven weeks 





Figure 1.12. A schematic timeline for the development of human globin genes 













The background and the key objectives for this study include:   
(i) Preliminary data indicated that MSC may play an important role in the 
aetiology of IH. This and other reports indicating primitive stem and 
progenitor cells in IH led us to investigate the presence and the 
phenotype of the stem cell populations present in IH, and their role 
in IH progression. 
(ii) Other studies in our laboratory have identified new putative therapeutic 
targets for IH treatment. This and the serendipitous discovery of 
propranolol as a treatment for IH led us to investigate the 
mechanism of propranolol action in inducing accelerated regression 













All IH tissue specimens used in this thesis were obtained from affected 
patients in accordance with a protocol approved by the Wellington Regional 
Ethics Committee. The IH specimens were then either fixed in 10% 
paraformaldehyde prior to wax embedding for immunohistochemistry analysis, 
or were used for tissue culture. Each specimen was categorised as either 
proliferating, involuting or involuted as previously described5. For this thesis a 
total of 12 proliferating and five involuted IH specimens were used with 




Plasticware and scalpels were obtained sterile from the manufacturers. 
Pipette tips, Eppendorfs, glass bottles, spatulae and forceps were 
appropriately autoclaved at 120°C for 20 mins prior to use. Handling of 
tissues and liquids were performed using aseptic techniques in a sterile Email 
Air Handling Class II Biological safety cabinet (AES Environmental Pty Ltd, 
Auburn, Australia) hereby mentioned as laminar flow hoods. 
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 All cell cultures were maintained in a Heracell incubator (Kendo 
Laboratory Products GmbH, Hanau, Germany) at 37°C in humidified air and 





HeLa cells were obtained from Dr Bronwyn Kivell, School of Biological 
Sciences, Victoria University of Wellington, and grown in Roswell Park 
Memorial Institute 1640 with glutamine (RPMI 1640 + glutamine, Gibco-BRL) 
medium supplemented with 10% foetal calf serum (FCS) and 2% Penstrep 
(100µg/ml streptomycin sulphate and 100µg/ml Penicillin G, Gibco-BRL), 
henceforth referred to as cell culture medium. Cells were maintained in 75cm2 
sterile cell culture flasks (Greiner Bio-One) and passaged by splitting the cells 
in a ratio of 1:3 twice weekly. 
 
2.1.3.2. SY5Y Cells 
SY5Y cells were obtained from Ms Sushila Pillal, School of Biological 
Sciences, Victoria University of Wellington and maintained in a similar fashion 





The mouse haemangioendothelioma (EOMA) cell line were obtained from Dr 
Anasuya Vishvanath, School of Biological Sciences, Victoria University of 




As required, cells frozen at -80°C were routinely thawed in a water bath at 
37°C prior to transferring to 15ml centrifuge tubes (Greiner Bio-one) 
containing 10mls of pre-warmed cell culture medium followed by 
centrifugation at 300 X g (1000 rpm) for 5 min at room temperature. 
Passaging cells involved decanting of the culture media followed by 
rinsing with sterile phosphate buffered saline (PBS). To dissociate the cells, 
an appropriate volume of pre-warmed trypsin-ethylene diamine tetra acetic 
acid (EDTA) (Invitrogen) (final concentration of 0.05-0.02% respectively) was 
added to a volume sufficient to cover the surface of the culture flasks. Flasks 
were then returned to the incubator for 2-5 min to allow for cell detachment. 
Media containing 5% FCS was then added at three times the volume of the 
trypsin, to quench the trypsin activity. The collected cells were then 
transferred to a 15ml polypropylene centrifuge tube and centrifuged at 300 X 
g (1000 rpm) for 5 min at room temperature. The supernatant was discarded 
and the remaining cell pellet resuspended in fresh cell culture media and 
equally divided into new culture dishes. 
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Following trypsinisation the percentage of live cells was determined by 
the use of trypan blue (Invitrogen) exclusion using a haemocytometer. Briefly 
10µL of the resuspended cell mixture was diluted in 10µL volume of 0.02% 
trypan blue in PBS and 10µL of this mixture was then loaded onto the 
haemocytometer, and the number of cells which excluded the trypan blue 





MCDB 131 powder medium (Sigma-Aldrich) containing trace elements and L-
glutamine was reconstituted with 1.18g/L sodium bicarbonate (Sigma-Aldrich) 
to a final volume of 1L with dH2O. To this reconstituted MCDB 131 media, 2% 
Penstrep and 2.5 µg/ml Amphotericin B (Sigma-Aldrich) were added prior to 
filter sterilisation through a 0.2µM filter (Greiner Bio-One). The media was 
then either used immediately or stored at 4°C for up to 8 weeks. 
 
2.2.2. Infantile Haemangioma Tissue Specimen Preparation 
All surgically excised IH specimens were initially cleansed of blood clots using 
sterile PBS. They were then all cut into roughly 2-mm explant pieces and 
submerged in disinfectant media, consisting of MCDB 131 containing 1.18 g/L 
sodium bicarbonate, 10% Penstrep, 25µg/ml Amphotericin B and 2mM L-
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Matrigel (Becton-Dickson) was thawed overnight at 4°C prior to use. A total of 
350µL of the matrigel was aliquoted into each chamber of a 24 well tissue 
culture plate (Greiner Bio-One) and plates were then left at room temperature, 
within the laminar flow hoods, to allow for gel formation. A piece of disinfected 
IH tissue was placed and allowed to settle in the newly formed gel for a further 
20 mins. Following setting of the gel around the IH tissue piece, 1.5mL of the 
sterile filtered MCDB 131 medium containing 1% FCS was added onto each 
well. All plates were incubated at 37°C in 3% CO2/97% air in a Heracell 
incubator (Kendo Laboratory Products). 
 
2.2.4. Isolation of Infantile Haemangioma Explant Derived Cells 
After 3 weeks in culture with media changed every 3 days, cells emanating 
from the IH explants were released from the Matrigel by treatment with 50 
caseinolytic units/well of dispase (Becton-Dickson) for 2 hrs at room 
temperature within the laminar flow hoods. The liquefied mixture was then 
collected and placed into a 15mL polypropylene centrifuge tube and the 
dispase activity quenched by diluting in a 10-fold excess of MCDB 131 media 
containing 5% FCS. Cells were harvested by centrifuging at 300 X g (1000 





Cells harvested from the haemangioma explant cultures were subsequently 
plated out in 96-well tissue culture plates (Raylab, Auckland, NZ) at a density 
of 1 x 105 cells per well. Cells were grown in MCDB 131 media, lacking FCS, 
but containing angiotensin II (Sigma-Aldrich) at concentrations of 0, 25, 100 
and 150µg/ml for a total of 6 days, with the media changed at day 3. 
 
2.2.5. Image Analysis 
Images of all cell culture experiments were obtained using an Olympus IX51 
inverted microscope (upgraded to IX71) fitted with phase contrast objectives 





Slides for immunohistochemistry were initially cleaned with 70% ethanol, dried 
and then submerged in a freshly prepared solution of 2% 3-amino-
propyltriethoxysilane (APES, Sigma) prepared in acetone for 1 min. Slides 
were then washed in water to remove excess APES and left to dry overnight 





5µM sections of formalin fixed paraffin embedded surgically excised IH 
tissues were cut using a Reichert-Jung Biocut microtome (Leica Instruments, 
Nussloch, Germany). Sections were floated in a water bath and subsequently 
transferred onto the APES-coated glass slides prior to drying overnight at 
room temperature. 
De-paraffinisation and rehydration of all slides prior to IHC staining was 
performed by an initial xylene stage (2 changes, 5 min each) followed by a 
graded ethanol series (100%, 90%, 80% and 70%) followed by a final rinsing 
stage in dH2O for 5 min.  
 
2.3.3. Immunocytochemistry Slide Preparation 
Cell cultures were collected from culture plates and were left to adhere onto 8-
chamber microscope slides (Becton Dickson) in 100 µL of cell culture 
media/chamber overnight prior to fixation with a total volume of 200µL of ice 
cold acetone/methanol (50:50) for 30 secs in preparation for immediate 
immunocytochemistry. 
The collection of the non-adherent blast structures involved decanting 
of the cell media from the culture plates followed by centrifuging at 300 X g 
(1000 rpm) for 5 min at room temperature and removal of the supernatant to 
allow for a final volume of 200 µL per slide before cytospinning using the 
Cytospin 3 (Thermo Shanden, Cheshire, UK). Slides were dried out on the 
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bench for 30 mins and fixed as mentioned above in acetone/methanol in 





Histochemical analysis of all paraffin sections were performed using Mayer’s 
haematoxylin and eosin (H&E). Slides underwent initial de-paraffinisation and 
rehydration, as mentioned previously, followed by dehydration in 90% and 
100% ethanol respectively (2 changes each for 5 mins) and were then cleared 
in xylene (2 changes, 3 mins each) followed by mounting in D.P.X (BDH 
Chemicals Ltd, Poole, UK). 
 
2.3.4.2. Fluorescent Immunohistochemistry 
Following routine deparaffinisation and rehydration slides were rinsed in tris 
buffered saline (TBS, made up of 2.42g/L Tris (Sigma-Aldrich) and 8g/L NaCL 
(Sigma-Aldrich), pH 7.5) containing 0.1% Tween-20 (BDH Chemicals) (TBST) 
for 5 min. Antigen retrieval was then performed by immersing the slides in 
coplin jars containing 10mM sodium citrate (pH 6) equilibrated in boiling water 
for 10 min. The coplin jars containing the slides were then allowed to cool to 
room temperature for 40 mins on the bench. Slides were then rinsed in TBST 
(3 changes, 5 mins each) followed by quenching of auto-fluorescence by 
washing the slides in 3 changes of 0.5% (w/v) sodium borohydride (Sigma-
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Aldrich) freshly prepared in TBS for 15 mins each. Slides were then washed in 
TBST and blocked using 5% bovine serum albumin (BSA, Sigma-Aldrich) 
prepared in TBST for 60 mins at room temperature. This was then followed by 
overnight incubation at 4°C with the appropriate primary antibody diluted in 
TBST, containing 1% BSA, accordingly as indicated in Table 2.3.4.4. Slides 
were then rinsed in TBST (3 changes, 5 mins each) and bound antibodies 
detected using secondary antibody amplification. The appropriate secondary 
antibody (Goat anti- Mouse alexa 488 (Invitrogen) or Chicken anti-Rabbit 
Alexa 594 (Invitrogen)) was incubated at room temperature for 2 hrs. 
Alternatively a tertiary cascade in which an initial incubation of 2 hrs with an 
anti-Rabbit digoxigenin (Roche diagnostics, NZ) was used prior to incubation 
with anti-digoxigenin-Rhodamine (Chemicon, Sydney, Australia) conjugate. 
Slides were washed in TBST in between antibody incubations. Cell nuclei and 
mounting were performed using 4’,6’-diamidino-2-phenylidole (DAPI) in Gold 
Antifade (Invitrogen). All coverslips were rinsed in 70% ethanol for 5 mins 
prior to mounting 
 
2.3.4.3. Fluorescent Immunocytochemistry 
Following fixation, attached cells were blocked with TBST containing 5% BSA 
for 1 hour prior to incubation with primary antibodies in a similar fashion as 
that for IHC. Antibodies used for immuno-cytochemistry were detected using 




Immunostained slides were viewed and captured using a Leica TCS 4D 
confocal laser-scanning microscope fitted with a krypton/argon laser (Leica 
Lasertechnik, Heidelberg, Germany). Images were then appropriately 





Antibody Marker  Species  Antibody Dilution  Source of Antibody 
GLUT‐1  Rabbit  1 in 500  Abcam 
Smooth muscle actin  Rabbit  1 in 400  Abcam 
CD34  Mouse  1 in 300  Abcam 
CD133  Rabbit  1 in 300  Abcam 
VEGFR‐2  Rabbit  1 in 400  Abcam 
Angiotensin converting enzyme  Mouse  1 in 200  Abcam 
Angiotensin receptor 1  Mouse  1 in 200  Abcam 
Angiotensin receptor 2  Rabbit  1 in 100  Abcam 
CD31  Mouse  1 in 400  Abcam 
CD29  Rabbit  1 in 300  Abcam 
Vimentin  Mouse  1 in 400  Abcam 
Sox‐9  Rabbit  1 in 300  Abcam 
Sox‐10  Rabbit  1 in 300  Abcam 
Nestin  Mouse  1 in 200  Abcam 
p75  Rabbit  1 in 200  Abcam 
Pref‐1  Rabbit  1 in 200  Abcam 
CD45  Rabbit  1 in 300  Abcam 
GATA‐2  Rabbit  1 in 300  Abcam 
TAL‐1  Rabbit  1 in 300  Abcam 
Brachyury  Rabbit  1 in 300  Abcam 
Glycophorin A  Mouse  1 in 200  Abcam 
Erythropoietin receptor  Mouse  1 in 200  Abcam 
Haemoglobin ζ  Rabbit  1 in 200  Abcam 
Nanog  Rabbit  1 in 300  Abcam 
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SSEA‐4  Mouse  1 in 300  Abcam 
OCT‐ 4  Rabbit  1 in 300  Abcam 
Human placental lactogen  Rabbit  1 in 300  Abcam 
Human chorionic gonadotrophin  Rabbit  1 in 300  Abcam 
Cytokeratin 7  Rabbit  1 in 300  Abcam 
Anti‐mouse Alexa 488  Goat  1 in 500  Invitrogen 














The observation of the segmental distribution in a subgroup of IH especially 
those associated with midline structural anomalies that constitute PHACES 
syndrome13 has led us to investigate the involvement of neural crest cells in 
the aetiology of this condition. Neural crest cells arise from the neural tube 
and migrate segmentally in the embryo giving rise to the peripheral nervous 
system, mesenchymal lineages and melanocytes45,64. Neural crest stem cells 
are characterised by the expression of the neurotrophin receptor (p75)45 and 
the transcription factors, Sox 9 & 1043,65,66. This chapter demonstrates the 
abundant expression of these neural crest stem cell associated proteins, p75, 
Sox 9 and Sox 10, on the endothelium of proliferating IH. We have previously 
shown that the cells in the endothelium also express a mesenchymal 
signature in that they also express the MSC markers, CD29 and vimentin, as 
well as the haematopoietic associated markers, CD34 and CD13367,68. It is 
intriguing that this unique expression pattern is also seen in cells of the 
primitive mesoderm. Cells of the primitive mesoderm additionally express the 
transcription factor, brachyury69.  
In this chapter, IH was stained immunohistochemically for proteins 
associated with the primitive mesoderm. Data is presented to demonstrate 
that the cells of the endothelium stain for markers of the primitive mesoderm 
and have a neural crest stem cell phenotype.   
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Additionally, the cells from the outgrowths that emanate from IH 
explants70, maintain a similar expression profile, suggesting that it is the cells 
of the endothelial layer that are responsible for the outgrowths seen in the 
explant model.  
Collectively these data support the hypothesis of IH being derived from 
primitive mesoderm and that the cells within the lesion have a neural crest 
stem cell phenotype and express proteins associated with haematopoietic, 
endothelial, neural crest and mesenchymal lineages. A model is proposed to 
account for the natural progression of IH based upon the multi-potent 
expression profile of the primitive mesoderm and their neural crest stem cell 





All experiments were performed by myself and the manuscript was written by 





































The expression of the haematopoietic markers, CD133 and CD34, and the 
primitive mesoderm marker, brachyury, as previously described in Chapter 3 
of this thesis has led us to investigate the expression of even more primitive 
haematopoietic markers in proliferating IH. 
 Endothelial progenitor cells (EPCs) are a population of progenitor cells, 
characterised by the expression of CD133, CD34 and VEGFR-2, that maintain 
the ability to differentiate toward both endothelial and haematopoietic 
lineages35. The presence of endothelial progenitor cells in proliferating IH has 
previously been demonstrated. Previous reports have highlighted an 
associated increased level of these cells within the circulation of affected 
individuals37, leading to the notion that IH arises from these progenitor cells36. 
 In this chapter data is presented to show that it is the same 
endothelium that expresses these EPC-associated markers, and in an attempt 
to unravel the link between primitive mesoderm and downstream EPCs we 
elected to investigate the expression of the intermediate haematopoietic 
associated markers. Intriguingly it was found that the endothelial layer also 
expresses markers associated with haemangioblasts, the precursor to EPCs, 
through the combined expression of angiotensin converting enzyme (ACE), 
the EPC-markers and primitive mesoderm specific transcription factor, 
brachyury. Given that haemangioblasts have been shown to generate 
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haematopoietic cells through a haemogenic endothelium phenotype, the 
expression of Tal-1/SCL, a transcription factor associated with the 
haemogenic endothelium was undertaken. Data is presented to show that Tal-
1 is expressed on the same endothelium of proliferating IH demonstrating the 
novel expression of this phenotype in this lesion. 
 These findings highlight a novel haemogenic endothelium phenotype 
and provide a new understanding into the origin of IH. The data also leads to 
our hypothesis that the increased levels of the downstream EPCs seen in the 
peripheral circulation of these patients is a consequence of shedding of these 
haematopoietic EPCs from the haemogenic endothelium phenotype but they 




All experiments and the drafting of the manuscript were carried out by myself 
























































The demonstration of a novel haemogenic endothelium phenotype within 
proliferating IH as described in Chapter 4, by the expression of primitive 
haematopoietic associated markers on an endothelium phenotype, suggest 
the possibility of the functional capacity of IH to produce downstream 
haematopoietic cells. In this chapter an investigation into the ability for 
proliferating IH to undergo erythropoiesis was undertaken. 
 Erythropoiesis is the process through which differentiation of 
multipotent haematopoietic stem cells produces downstream mature 
enucleated erythrocytes71. Functional erythropoiesis is further defined by the 
ability to demostrate certain  stages of erythroid differentiation. In this chapter 
data is presented to show the in vitro stages of haematopoiesis, in which 
initial blast-like cells are shown to arise from the cells emanating from 
proliferating IH explants that then form blast colonies and eventually give rise 
to erythrocytes. These are all key stages in erythropoiesis. It is intriguing that 
we have previously confirmed the expression of the neural crest marker, p75, 
and the EPC markers, CD133, CD34 and VEGFR-2, on these cells as 
presented in Chapter 3 of this thesis. This chapter confirms the functional 
capacity of this primitive phenotype to undergo functional erythropoiesis. 
 To understand erythropoiesis involves an understanding of the various 
stages of in utero erythropoiesis. The stages of erythropoiesis are named 
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according to the sites of each stage, namely, in chronological order, 
mesoblastic, hepatic and eventual myeloid49. Concomitant with the changes in 
the embryonic sites of erythropoiesis are the developmental switches in the 
expression of the various isoforms of haemoglobin (Hb) chain expressed. The 
initial embryonic (ζ2ε2) Hb switches to foetal (α2γ2) Hb at about 6-7 weeks of 
gestation and is eventually replaced by the adult (α2β2) Hb postnatally61,62. 
 This chapter reports the expression on the cells of the endothelium in 
proliferating IH of the erythropoietin receptor (EPO-R), the receptor for 
erythropoietin, which is the crucial cytokine required for erythropoiesis as well 
as the embryonic Hbζ protein. The expression of these proteins suggests the 
potential for proliferating IH to undergo primitive erythropoiesis. Data is 
provided to demonstrate that the in vitro cultured IH biopsies are able to 
undergo erythropoiesis, such that the cells emanating from the explants are 




The concept of primitive erythropoiesis, all in vitro and IHC experiments were 
performed by myself. The RT-PCR experiements were performed by Dr 



































An understanding of the cellular and molecular events involved in the life 
cycle of IH remains enigmatic, and the precise origin of the fibro-fatty 
residuum during involution is unknown. The MSCs present within IH have 
been presumed to be recruited from adjacent niches and have been proposed 
to contribute to the fibro-fatty residuum seen during the involuted phase of this 
tumour39. 
 However, that we have recently demonstrated a neural crest stem cell 
and mesenchymal associated protein expression profile on the cells of the 
endothelium of proliferating IH capillaries described in Chapter 3 of this thesis. 
Further to this, in the same chapter we have also demonstrated that cells that 
migrate out from proliferating IH explants, also express the same markers. We 
have previously hypothesised that these cells form the downstream definitive 
mesenchymal lineages that predominate in the fatty tissue seen in the 
involuted lesions.  
This notion that the source of the MSCs that ultimately give rise to the 
fibro-fatty deposition of involuted lH is derived from the endothelium of 
proliferating IH lesions is a novel concept.  
In this chapter I propose that the source of the MSCs that ultimately 
gives rise to the fibro-fatty deposition of involuted lH is derived from the cells 
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that form the endothelium of the capillaries of proliferating IH lesions. This is a 
novel concept that has not previously been proposed. 
 While the cells of the endothelium have many characteristics of 
immature endothelial cells (e.g., expression of CD31 and CD34)29. I propose 
that these endothelial-like cells are in fact a primitive population of cells with 
the capacity to differentiate into both endothelial cells and into terminal 
mesenchymal derived adipocytes. Such an unorthodox hypothesis raises the 
question of what factors, if any, are regulating the terminal differentiation into 
adipocytes. It is in this chapter that I discuss the involvement of pre-adipocyte 
factor-1 (Pref-1)72 as one possible factor expressed during proliferation and is 
lost during involution that may be crucial in regulating terminal mesenchymal 
differentiation. 
 This chapter also demonstrates that it is the same cells that migrate out 
from the proliferating IH explants, as previously characterised in Chapter 3, 
that possess the potential to differentiate into terminal mesenchymal tissues. 
 The findings of a primitive phenotype of the endothelial layer of 
proliferating IH with the ability to differentiate down mesenchymal lineages, 
yet are inhibited from doing so during proliferation represents a significant 






The novel concept of the endothelium of proliferating IH as the source of the 
adipocytes coupled with the expression of Pref-1 as a mesenchymal 
differentiation inhibiting protein was conceived by myself. The IHC 
experiments and the draft for the manuscript was written by myself and edited 
by my supervisors. The RT-PCR and functional differentiation experiments 





























The expression of OPG and its ligand TRAIL in IH was previously 
demonstrated by Vishvanath et al11 who suggest that OPG was part of a 
critical pathway in the maintenance of anti-apoptosis seen during cellular 
accumulation of the proliferating phase of IH. Further to this OPG, has also 
been demonstrated to be critical in the recruitment and differentiation of 
osteoclasts via its actions on RANK, acting on RANKL to inhibit osteoclastic 
bone resorption, presumably through inhibition of osteoclast differentiation47. 
This chapter discusses the novel implications of OPG and TRAIL in 
anti-apoptosis within IH. Interesting, however, is the observation that RANKL-
positive cells are located within the interstitium of these proliferating lesions. 
This unique and exclusive expression pattern of the expression of RANKL 
highlights a potential primitive macrophage population within proliferating IH. 
As to whether these cells are recruited into the tumour or whether they are a 







Demonstration of the presence of RANKL-positive cells and its incorporation 
into the body of the manuscript were performed by me, all other experiments 
in this manuscript and the concept of OPG and TRAIL together with the 
drafting of the manuscript was done by Dr Vishvanath. Final editing was done 































































Chapter 4 describes the expression of angiotensin converting enzyme (ACE) 
on the putative haemogenic endothelium of the capillaries of proliferating IH. 
The demonstration of the expression of ACE is significant as it suggests a 
possible role of the renin-angiotensin system (RAS) in the biology of IH, and  
a potential mechanism to account for the action of β-blockers, such as 
propranolol, in accelerating involution of proliferating IH. 
 In this chapter I have demonstrated the expression of angiotensin 
receptor 2 (ATR2), but not angiotensin receptor 1 isoform within the capillaries 
of proliferating IH. This is intriguing as recent studies have demonstrated 
critical involvement of ATR2 during primitive haematopoiesis with the 
angiotensin II (ATII) being the active peptide73.  
Additionally, data is presented to show that the administration of ATII to 
cells derived from proliferating IH explants causes them to form blast colonies 
during cell culture. The blasts express similsr proteins to those seen in EPCs 
that have been demonstrated to be involved in IH progression. It is intriguing 
to suggest that these EPCs/blasts are indeed downstream effects of 
excessive ATII production. 
Interestingly white, female, and premature infants who have higher 
incidence of IH also have higher levels of physiological renin compared with 
black, male, and full-term infants74-76. Renin is known to convert 
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angiotensinogen to angiotensin I77, which is then converted to the vaso-active 
ATII within the tumour to act in an autocrine/paracrine fashion to promote 
proliferation of the EPC phenotypic haemogenic endothelium, as previously 
discussed in Chapter 4. 
 This chapter also hypothesises that IH is governed by the RAS. High 
levels of renin during the proliferative phase of IH, lead to elevated levels of 
ATII which causes proliferation of the haemogenic endothelium.  
 
8.2. Contribution 
All experiments were performed by myself, the manuscript was written by 






















































We have previously proposed an ESC origin for IH, as discussed in Chapter 3 
of this thesis. This has led us to further investigate the expression of ESC-
associated markers within IH. 
 ESCs are pluripotent cells typically derived from the inner cell mass of 
the blastocyst78,79, and the identification of the unique signature profile of 
ESCs has enabled the demonstration of the expression of certain proteins 
associated with an ESC phenotype. Further characteristics of ESCs are their 
ability to form all three germ layers in vitro, and teratomas in vivo80. 
 Proteins associated with ESCs include Oct-4, a POU transcription 
factor which has been demonstrated in pluripotent primitive embryonic cells81; 
STAT-3, a signal transducer and activator transcription factor critical in ESC 
renewal82; SSEA-4, a cell surface marker associated with ESCs78; and Nanog, 
a transcription factor crucial for the maintenance of ESC pluripotency83. 
 In this chapter I report the expression of Oct-4, STAT-3 and SSEA-4 on 
the endothelium of the capillaries within proliferating IH. Interestingly Nanog is 
not expressed by the cells of the endothelium, but by cells in the interstitium.  
 The expression of only some, but not all ESC-associated markers on 
two different populations of cells within proliferating IH suggests a cellular 
origin of IH downstream of ESCs. The two possibilities discussed in this 
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chapter to account for this finding are that the Nanog-positive cells are a 
derivation from the more primitive endothelium, or alternatively there may be 
two different populations of primitive cells in proliferating IH. 
 These findings reveal novel primitive populations of stem cells within 
proliferating IH, that are downstream of ESCs, as determined by the 





All IHC experiments, apart from the stat-3, and drafting of the manuscript 
were performed by myself, and edited by my supervisors. The stat-3 
experiment was performed by Dr Vishvanath and the RT-PCR experiements 










































































































Chapter 9 demonstrates the expression of hESC markers on two distinct 
populations of cells, suggesting a possible cellular origin downstream of hESC. 
This knowledge coupled with previous reports highlighting the similarities in 
protein expression of proliferating IH and placenta6,84-86 pointed to the 
trophoblast87 as a possible cellular origin of this enigmatic condition. 
 This chapter demonstrates the expression of the trophoblast-
associated proteins namely human placental lactogen (hPL)88 and human 
chorionic gonadotrophin (hCG)88, but not human leucocyte antigen-G (HLA-G) 
or cytokeratin 7 (CK7)89 on the haemogenic endothelium layer of proliferating 
IH. These observations confirm that trophoblasts are possibly not the origin of 
IH, which in turn focused our attention on the mesenchymal core cells of the 
placental chorionic villi. These cells, which are derived from extra-embryonic 
primitive streak have been reported to express hCG90 and hPL but not HLA-G 
or CK791, similar to the expression profile of proliferating IH endothelium. In 
support of this placental chorionic mesenchymal core cellular origin of IH, is 
the ability for these cells to undergo vasculogenesis and the formation of a 
haemogenic endothelium92, consistent with the findings presented in Chapters 
3 to 5. This is fascinating as it may explain the higher incidence of these 
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tumours in infants that have undergone in utero procedures, such as 
aminiocentesis93 or chorionic villous sampling93. This observation suggests 
that trauma associated with in utero samplings results in shedding of the 
placental chorionic villous mesenchymal core cells and is consistent with 





The novel concept of the placental chorionic mesenchymal core cell origin of 
IH was conceived by myself. The initial IHC experiments and the draft for the 
manuscript was written by myself and edited by my supervisors. Cofirmation 
of the expression of the placental by repeating the IHC experiements on other 






































There is a need for intervention in about 10% of IHs, as there is an inherent 
risk to the infant’s life or function due to either tissue distortion or destruction. 
The mainstay of intervention for problematic proliferating IH is 
pharmacological therapy, High-dose corticosteroids being the first line of 
therapy, until the serendipitous discovery of the dramatic effect of propranolol 
in this condition25. Propranolol has become the preferred treatment for this 
condition27,94-97. 
 In this chapter I describe our research group’s experience with the use 
of propranolol in this group of patients, and further to this, we attempt to 
explain the observed effect of this pharmacologic agent with regard to the 
results presented in earlier chapters. In particular I attempt to identify critical 
pathways governing the stem cell biology of these tumours in an attempt to 
identify safer alternatives to this particularly ‘vulnerable’ population affected by 
this condition. These findings have led to a trial in the use of captopril, an ACE 






My involvement in the clinical reports involved analysis and editing of the 
manuscripts, whereas for the review paper the manuscript was drafted by 






























































































































































































IH, the most common tumour of infancy, affects an average of 10% of infants 
with a predilection for Caucasian, female and premature infants4,5. IH 
undergoes an initial proliferation within the first year of life, followed by 
spontaneous involution that may take up to ten years5; the proliferating phase 
is characterised by aggressive angiogenesis whereas the involuted phase by 
fibrofatty deposition. 
 
12.1. Key Findings 
12.1.1. Renin-Angiotensin System in Infantile Haemangioma 
 
The work in this thesis has shown a role for the renin-angiotensin system 
(RAS) in IH, in the biology of IH and accounts for the observed propranolol-
induced accelerated regression of IH. The observed effect of propranolol and 
the observation that renin levels are higher in Caucasian, female and 
premature infants who have an increased incidence of IH, led me to 
investigate the expression of components of the RAS in IH. This work shows 
that propranolol exerts its therapeutic effects via inhibition of renin activity, 
rather than through beta adrenergic receptors as proposed by others25,98.  
The role of renin in the aetio-pathology of IH was supported by 
previous observations showing very high levels of renin in infants compared 
with adults and increased levels of renin in patients with a higher risk of 
developing IH, Caucasian (compared with back), female (compared with male) 
and premature (compared with term) infants. The identification of key 
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components of the RAS, ACE, ATII and ATR2 and in vitro experiments 
demonstrating ATII-induced IH blast proliferation, confirm a key role for the 
RAS in the biology of IH90. The novel discovery of the RAS pathway in the 
biology of IH identifies a potential role for ACEi as a potential therapy for IH. A 
clinical trial using captopril, an ACEi, induced accelerated involution as 
predicted by our model and unequivocally proved the role of the RAS in IH 
progression. This concept has revolutionised the understanding of this 
enigmatic condition. However our preliminary results on the use of ACEi, 
while sucessful were less dramatic compared with propranolol. I hypothesised 
that the levels of ATII available to IH, might involve a balance and/or 
combination of endocrine and paracrine/autocrine systems. I have recently 
(unpublished results) demonstrated the presence of local RAS/non-RAS 
pathways leading to the local production of the vasoactive peptide ATII in IH. 
This observation suggests that targeting the peptides upstream of ATII will 
possibly allow for the development of more effective treatment. Such 
treatment approach would negate the upstream accumilation of ATI resulting 
from treatment with ACEi which may be subsequently acted upon by other 
locally expressed proteases to generate vasoactive peptides other than ATII.    
 
12.1.2. Osteoprotegerin in Haemangioma 
 
The novel identification of OPG in IH suggests a potential role for OPG in the 
inhibition of apoptosis via the TRAIL receptors in proliferating IH. The 
identification of abundant expression of OPG on immature microvessels but 
not the mature vessels suggest an important role for the anti-apoptotic TRAIL 
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pathway during proliferation11. It is intriguing that ATII has also been 
demonstrated to promote secretion of OPG99. This  further supports a critical 
role of the RAS, both in inducing proliferation and also in the maintenance of 
anti-apoptosis during the proliferaion of IH.   
Other reported functions of OPG involve its role in the stress response, 
possiblity due to inflammation, which is also a trigger for the formation of new 
vessels. It is my opinion that the restricted expression of OPG on the 




12.1.3. Haemogenic Endothelium and Primitive Erythropoiesis in 
Infantile Haemangioma 
 
 IH has been proposed to be derived from circulating EPCs, based on the 
identification of increased levels of circulating EPCs in the peripheral blood of 
the affected patients. Exploration of this idea led us to discover not only the 
expression of EPC-like markers on the endothelium of proliferating IH, but 
also the expression of more primitive haematopoietic markers, ACE, Tal-
1/SCL and Gata2, denoting a haemogenic endothelium100. In further support 
of our suggestion that IH is derived from a haemogenic endothelium was the 
demonstration of expression of primitive erythropoietic associated proteins 
EPO-R and Hbζ as described in Chapter 5101. The proof that IH is a 
haemogenic endothelium is proven by the functional capacity of proliferating 
IH explant derived cells to form erythrocytes in vitro. These findings highlight 
181 
 
IH not only as a potential extramedullary source of erythropoiesis, but also as 
a novel model for studying human primitive haematopoiesis. 
 
12.1.4. Primitive Mesoderm with a Neural Crest Stem cell phenotype in 
Haemangioma 
 
 The process of primitive haematopoiesis and development of IH involve the 
identification of primitive mesoderm, crucial for forming downstream cells 
capable of primitive haematopoiesis. These primitive mesodermal cells are 
characterised by the expression of the transcription factor brachyury on the 
endothelial layer of proliferating IH. These cells also express the neural crest 
stem cell associated markers, p75, Sox-9 & Sox-10, highlighting these cells 
as potentially being the most primitive population in the proliferating capillaries. 
This unique neural crest phenotype may account for segmental IH, some of 
which are associated with PHACES syndrome, which is discussed later in this 
chapter102.  
 
12.1.5. Mesenchymal Stem Cells in Haemangioma 
 
 The fibro-fatty deposition that predominates during involution highlights an 
observed change in the predominant cell type compared with those present 
during proliferation. This could either be explained by the invasion of MSC 
from adjacent niches that eventually differentiate into adipocytes as previously 
proposed39, or by the identification of an innate MSC population within 
proliferating IH lesions. The data presented in Chapter 6 shows the 
expression of MSC proteins (vimentin and CD29) and mesenchymal 
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differentiation inhibition protein (pref-1) by the cells of the endothelium (ref). 
These results are further supported by functional experiments highlighting the 
expression of the same proteins by cells emanating from proliferating IH 
explants, which show functional ability to differentiate into terminal 
mesenchymal cells, namely adipocytes and osteoblasts103. This confirms a 
mesenchymal differentiation potential of the haemogenic endothelium. My 
model does not exclude the possibility of invasion of MSCs from 
adjacent/other niches, however, my data confirm the presence of an innate 
MSC population within IH. 
 
12.1.6. Embryonic Stem Cell expression in Infantile Haemangioma 
 
 The demonstration of a neural crest stem cell phenotype in IH, led us to 
investigate whether the IH lesions are derived from hESCs, from which during 
normal development, neural crest stem cells can be directly derived. 
Surprisingly hESC markers are identified, but their expression is identified on 
two different cell populations within proliferating IH lesions. One population 
express Oct-4, SSEA-4 and STAT-3 and is restricted to cells of the 
endothelium, whilst the other population that express nanog is located in the 
interstitium but none of the other ESC markers. This expression pattern within 
proliferating IH is intriguing, and at this stage we can only infer that either the 
Oct-4-positive cells within the endothelium represent the true cellular origin of 
IH which give rise to the ‘more’ downstream nanog-positive cell or that there 
are simply two different primitive populations of cells within proliferating 
lesions. However, more recent data has confirmed that the nanog-positive 
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cells are also express mast cell markers (unpublished results), inferring a 
primitive myeloid phenotype that is most likely derived from the haemogenic 
endothelium. 
 
12.1.7. Placental Chorionic Villous Mesenchymal core cellular origin of 
Infantile Haemangioma 
 
Previous studies have reported on the similarities in the expression profile 
between IH and the placenta, and suggest a placental origin for IH6,84,86 
eventhough the IHC staining pattern is not completely consistent with a 
trophoblast origin87. These reported similarities between IH and placenta, and 
the ambiguities of previous investigations led us to investigate the expression 
of trophoblast-associated markers in IH. Our data demonstrate the expression 
of the placental markers, hPL and hCG, but not CK7 or HLA-G. These data 
and the controls used, support the cellular origin of IH as being the 
mesenchymal core cells of the placental villi. This suggestion supports our 
earlier findings, as these placental mesenchymal core villous cells are derived 
from the primitive streak, that also expresses brachyury.84 This is quite 
intrugiung in that the primitive streak also gives rise to the primitive mesoderm 
of the embryonic yolk sac, the site of embryonic Hbζ production, as well as 
the site of de novo haemogenic endothelium formation. Taken as a whole, the 
data strongly supports a placental villous mesenchymal core cell origin for IH. 
Embolisation of these cells early in the embryonic development may account 
for segmental lesions, and embolisation that occurs later in the embryonic 
development results in localised lesions.  
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 Our neural crest cell theory as giving rise to the PHACES has recently 
been quoted in a published article104 ‘A new report emphasizes the possibility 
of an underlying neural crest abnormality contributing not only to the 
cardiovascular malformations but also to the hemangiomas [Itinteang et 




12.1.8.  Summary of Key Findings 
 
 The key finding of this thesis is that IH is developmental anomaly of stem cell 
proliferation and differentiation. These statements have been confirmed by the 
characterisation of a novel stem cell population in IH and the critical role of the 
RAS in both the natural biology of IH and the observed effect of novel 
treatments, such as propranolol and ACEi. 
The physiologically higher levels of renin during infancy which taper off 
once a child reaches their first year of life and is normalised by the age of ten, 
and the high levels in Caucasian (compared with black), female (compared to 
male) and in premature (compared with termed) infants thus account for both 
the natural history of IH and the increased prevalence in female, Caucasian 
and premature infants. 
Our data suggests that it is likely that placental mesenchymal core 
villous cells are the cell of origin of IH. We infer that these stem cells are 
embolised to the foetus in utero, and account for the increased risk of IH 
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following invasive in utero investigations, such as amniocentesis and 
chorionic villous sampling. These cells depending on the timing of 
embolisation may also account for the clinical presentations of IH, whereby 
early embolisation leading to PHACES syndrome whereas ‘late’ embolisation 
accounting for discrete lesions. 
 Figure 12.1 highlights the key stages of stem cell differentiation during 
IH development. Physiologically high levels of circulating renin during infancy, 
favours formation of endothelial progenitor cells (EPCs) and haematopoiesis. 
As renin levels decrease during childhood resulting in reduced angiotensin II 
levels with subsequent reduced OPG. The net result of this is reduced EPCs, 
promotion of apoptosis and a release of the block on mesenchymal 





























Figure 12.1. Our proposed model of the cellular lineages of IH and the role of 
the renin-angiotensin system and osteoprotegerin (OPG) in the development 
IH. 
 
12.2. Future Directions in Haemangioma Research 
 
12.2.1.  Angiotensin II  
 
An understanding of the key peptides leading to the formation of ATII and its 
application to the developmental biology of IH highlights a future area in the 
regulatory steps in the biology of IH and the development of novel treatment 
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strategies for IH. This thesis has investigated the RAS pathway and its 
inferred role in IH development. However, other non- RAS pathways which 
also lead to the formation of the vasoactive ATII is now the topic of further 
investigation by our group. Preliminary data from our group have confirmed 
abundant expression of cathepsin B, an enzyme responsible for converting 
pro-renin to renin, and cyclo-oxgenase-2 (COX-2) within proliferating IH 
(Figure 12.2), constituting paracrine/autocrine non-RAS pathway within IH.  
Figure 12.3, illustrates non-renin/ACE pathways leading to ATII formation. We 
have previous shown the expression of chymase by mast cells within IH (ref) 
and the obvious implications for their role in the biology in IH. The applications 
of the role of ATII in IH and stem cell biology are still in their early stages and 
further research into their exact role and interplay with other vasoactive 
peptides, such as VEGF, will need to investigated. 
 
    
Figure 12.2. IHC of proliferating IH illustrating expression of COX-2 (red, left panel) 








Figure 12.3. A schema illustrating both the RAS and the non-RAS pathways leading 
to ATII formation (Adapted from Zaman, et al105). 
 
12.2.2.  Stem Cell Biology of Infantile Haemangioma  
 
The origin of IH has remained enigmatic. Identification of critical stages in 
stem cell differentiation in IH has enabled a better understanding of this 
condition. Future research in the development of animal models for IH will 
need to address not only the environmental cytokine milieu, but also an 
appreciation for the heterogeneity of the stem cell population in IH. We now 
have data demonstrating that the nanog-positive cells in the interstitium of 
proliferating IH contained in Chapter 9, are the mast cells previously shown in 
IH5. Whether these mast cells originate from a primitive myeloid lineage 
derived from the haemogenic endothelium during primitive haematopoiesis or 
whether they are an independent primitive population within IH is a topic of 
our current research. These observations have highlighted some of the key 
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stem cell components that make up IH. It is therefore possible to infer that 
until such a model encompassing all facets of IH biology that the true in vivo 
model of IH maybe established, perhaps in an orthoptic model (Figure 12.4), 
thus enabling future advances in research into IH and a further appreciation of 
the complex aetio-pathology of this enigmatic condition. 
 
    
Figure 12.4. The development of an in vivo IH mouse model is dependant on the 
heterogenity of the stem cell population in IH. 
 
12.2.3.  Tissue Engineering  
 
The stem cell biology of IH and the ability of innate stem cells within IH to 
differentiate into a variety of downstream cellular elements such as 
adipocytes, osteoblasts and erythrocytes, further highlights the potential use 
of IH derived stem cells. These multipotent stem cells can be further used as 
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models for developing a better understanding of the cytokines and the 
differentiation pathways that they control in maintaining differentiation. These 
pathways may potentially provide the launching platform for the development 
of directed stem cell differentiation and its myriad of applications in the field of 
tissue engineering (Figure 12.5).  
 
 
Figure 12.5. The clinical applications for the future use of tissue engineering will 




12.2.4.  Tumour Vasculogenesis  
 
There is accumulating evidence showing cancer stem cells in solid tumours 
are dependant upon the ability to establish their own blood supply for nutrient 
access, but which also facilitates metastasis106. The development of a tumour 
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blood supply, tumour vasculogenesis, is dependant on the resident stem cell 
population with vascuologenic differentiation capacity. Our research in 
vasculogenesis in IH has highlighted the expression of key proteins in the 
resident stem cell populations (Figure 12.6).  Our preliminary work in head 
and neck cancer, based on our discovery of the presence of primitive cells 
within a variety of head and neck cancers and the involvement of the RAS in 
these tumours is an exciting avenue for further research.  
   
Figure 12.6. The formation of vascular tubes derived from endothelioma tumour cells 
requires the presence of IH stem cells when grown in matrigel. Images taken day 2 
(left) and day 6 (right) in culture. 
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